INMARKTM now enrolling: first study to evaluate the effect of OFEV (nin
First time the effect of OFEV® is being explored on change of biomarkers...
2016-07-01
文传商讯
New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedan
For the first time the analysis shows that disease progression is similar in...
2016-06-27
文传商讯
Samsung Bioepis Announces New Data on Three Anti-TNF-伪 Biosimilar Mole
Switching data on Benepali® (etanercept), Flixabi® (infliximab) and ...
2016-06-15
文传商讯
SES Deploys SATMED e-Health Platform in Benin to Improve Treatment of I
Second SATMED deployment in Benin with NGO partner Fondation Follereau Luxem...
2016-06-15
文传商讯
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadl
Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a mo...
2016-06-04
文传商讯
IL-23 inhibitor risankizumab induces remission in Phase II study in pat
After 12 weeks, approximately twice as many patients with moderate-to-severe...
2016-05-26
文传商讯
Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosi
INCHEON, Korea -- (BUSINESS WIRE) --Samsung Bioepis Co., Ltd. today announce...
2016-05-24
文传商讯
South Korea is first to approve next generation lung cancer treatment o
Olmutinib* (BI 1482694 / HM61713) is first TKI therapy approved in South Kor...
2016-05-21
文传商讯
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about st
First-of-its-kind survey investigated knowledge of stroke and perceptions ab...
2016-05-12
文传商讯
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivot
The trial will evaluate efficacy and safety of nintedanib* as a first-line o...
2016-05-11
文传商讯
